Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 11/20 | 0.64 |
| ▸ | TGM2 | P21980 | 1/20 | 0.63 |
| ▸ | NT5E | P21589 | 1/20 | 0.57 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.56 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.54 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.54 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.53 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.53 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.53 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.52 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.52 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.52 |
| ▸ | HINT1 | P49773 | 2/20 | 0.52 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.51 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.51 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.51 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29657998 | 0.99 | KRAS (0.65) | KRASTGM2NT5EFUT5TAS1R3 | |
| SCHEMBL17824390 | 0.94 | TAS1R3 (0.61) | KRASTGM2NT5ETAS1R3TAS1R1 | |
| SCHEMBL30576907 | 0.94 | KRAS (0.65) | KRASTGM2NT5EFUT5TAS1R3 | |
| SCHEMBL30037364 | 0.90 | TGM2 (0.66) | KRASTGM2NT5EFUT5TAS1R3 | |
| SCHEMBL23176397 | 0.86 | TGM2 (0.70) | KRASTGM2NT5EFUT5P2RY6 | |
| SCHEMBL21067995 | 0.86 | TGM2 (0.70) | KRASTGM2NT5EFUT5P2RY6 | |
| SCHEMBL21256201 | 0.86 | TGM2 (0.70) | KRASTGM2NT5EFUT5P2RY6 | |
| SCHEMBL4308355 | 0.86 | TGM2 (0.70) | KRASTGM2NT5EFUT5P2RY6 | |
| SCHEMBL234673 | 0.86 | TGM2 (0.70) | KRASTGM2NT5EFUT5P2RY6 | |
| SCHEMBL877839 | 0.86 | TGM2 (0.70) | KRASTGM2NT5EFUT5P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025016899-A1 | SPIROCYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2025-01-23 | — | — | WO | disclosed |
| US-20240083857-A1 | 2-Methyl-Quinazolines | Bayer Pharma AG (DE) | 2024-03-14 | — | — | US | disclosed |
| US-20230029385-A1 | 2-METHYL-AZA-QUINAZOLINES | BAYER AG (DE) | 2023-01-26 | — | — | US | disclosed |
| CN-115315424-A | 2-methyl-aza-quinazolines | 拜耳公司 | 2022-11-08 | — | — | CN | disclosed |
| US-20220274979-A1 | 2-METHYL-AZA-QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-09-01 | — | — | US | disclosed |
| EP-4045505-A1 | 2-METHYL-AZA-QUINAZOLINES | Bayer Aktiengesellschaft (DE) | 2022-08-24 | — | — | EP | disclosed |
| US-20220235013-A1 | 2-METHYL-QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083857-A1 | 2-Methyl-Quinazolines | NRAS, KRAS, KSR2 | KRAS 2/4885TGM2 2603/4885NT5E 4165/4885 |
| US-20230029385-A1 | 2-METHYL-AZA-QUINAZOLINES | AZI2, DNMT1, TPMT | KRAS 145/4885TGM2 2682/4885NT5E 1345/4885 |
| US-20220274979-A1 | 2-METHYL-AZA-QUINAZOLINES | AZI2, DNMT1, TPMT | KRAS 116/4885TGM2 2752/4885NT5E 1477/4885 |
| US-20220235013-A1 | 2-METHYL-QUINAZOLINES | NRAS, KRAS, KSR2 | KRAS 2/4885TGM2 2603/4885NT5E 4165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.